Oncoinvent ASA (OSL:ONCIN)
Norway · Delayed Price · Currency is NOK 45.90
-0.10 (-0.21%)
Mar 30, 2026, 1:59 PM CET
Oncoinvent ASA Revenue
Oncoinvent ASA had revenue of 5.98M NOK in the quarter ending June 30, 2025, with 17,750.75% growth. This brings the company's revenue in the last twelve months to 20.00M, up 247.12% year-over-year. In the year 2024, Oncoinvent ASA had annual revenue of 8.10M with 39.95% growth.
Revenue (ttm)
20.00M
Revenue Growth
+247.12%
P/S Ratio
10.30
Revenue / Employee
555.44K
Employees
36
Market Cap
205.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.10M | 2.31M | 39.95% |
| Dec 31, 2023 | 5.79M | -493.00K | -7.85% |
| Dec 31, 2022 | 6.28M | -4.80M | -43.31% |
| Dec 31, 2021 | 11.08M | 705.85K | 6.80% |
| Dec 31, 2020 | 10.38M | -1.03M | -9.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 118.21M |
| Aqua Bio Technology ASA | 101.51M |
| Arctic Bioscience AS | 45.90M |
| SoftOx Solutions AS | 15.58M |
| PCI Biotech Holding ASA | 4.69M |
| Nykode Therapeutics AS | 4.57M |
| Lytix Biopharma AS | 377.00K |
| Circio Holding ASA | 123.00K |
Oncoinvent ASA News
- 4 weeks ago - Oncoinvent ASA: Second half 2025 results - PRNewsWire
- 1 year ago - BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ... - GuruFocus